Adherex Technologies (FENC) Stock Price, News & Analysis

Company Overview

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Key Stats

• Today's Range: $6.90 to $7.25
• 50-Day Range: $5.77 to $8.87
• 52-Week Range: $5.65 to $9.92
• Volume: 211,119 shs
• Average Volume: 147,898 shs
• Market Capitalization: $239.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.80
• Consensus Rating: Moderate Buy

Adherex Technologies Stock Analysis - MarketRank™

Adherex Technologies scored higher than 79% of companies evaluated by MarketBeat, and ranked 156th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adherex Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Adherex Technologies has a consensus price target of $14.80, representing about 113.6% upside from its current price of $6.93.

Amount of Analyst Coverage

Adherex Technologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 286.36%

Earnings Growth

Earnings for Adherex Technologies are expected to grow by 286.36% in the coming year, from $0.22 to $0.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adherex Technologies is -20.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adherex Technologies is -20.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adherex Technologies has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.06% of the float of Adherex Technologies has been sold short.

Short Interest Ratio / Days to Cover

Adherex Technologies has a short interest ratio ("days to cover") of 5.25.

Change versus previous month

Short interest in Adherex Technologies has recently increased by 1.90%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adherex Technologies does not currently pay a dividend.

Dividend Growth

Adherex Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.45

News Sentiment

Adherex Technologies has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Adherex Technologies this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for FENC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Adherex Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adherex Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,822.00 in company stock.

Percentage Held by Insiders

11.76% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/24/2026
• Today: 5/09/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FENC
• CIK: 1211583
• Web: www.fennecpharma.com
• Phone: 919-636-4530
• Fax: 919-890-0490
• Employees: 10
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Adherex Technologies: $14.80
• High Price Target: $18.00
• Low Price Target: $13.00
• Potential Upside/Downside: +113.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 31.50
• P/E Growth: N/A
• Net Income: -$9.74 million
• Net Margins: -22.62%
• Pretax Margin: -21.58%
• Return on Equity: -183.18%
• Return on Assets: -15.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.37
• Quick Ratio: 6.23

Sales & Book Value

• Annual Sales: $44.64 million
• Price / Sales: 5.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 6.66

Miscellaneous

• Outstanding Shares: 34,540,000
• Free Float: 30,479,000
• Market Cap: $239.36 million
• Optionable: Optionable
• Beta: 0.91